High-grade glioma mouse models and their applicability for preclinical testing

被引：60

作者：

de Vries, Nienke A. ^{[1
]}

Beijnen, Jos H. ^{[2
,3
]}

van Tellingen, Olaf ^{[1
]}

机构：

[1] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Clin Chem, NL-1066 CX Amsterdam, Netherlands

[2] Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands

[3] Univ Utrecht, Fac Pharm, Div Drug Toxicol, NL-3584 CA Utrecht, Netherlands

来源：

CANCER TREATMENT REVIEWS | 2009年 / 35卷 / 08期

关键词：

Glioma; Mouse models; Genetic engineering; Intervention studies; Non-invasive imaging; GROWTH-FACTOR RECEPTOR; BLOOD-BRAIN-BARRIER; NEURAL STEM-CELLS; MALIGNANT GLIOMA; 3-KINASE/MAMMALIAN TARGET; GENETIC ALTERATIONS; SIGNALING PATHWAYS; MUTANT MICE; SOMA SIZE; TUMORS;

D O I：

10.1016/j.ctrv.2009.08.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

High-grade gliomas (WHO grade III anaplastic astrocytoma and grade IV glioblastoma multiforme) are the most common primary tumors in the central nervous system in adults. Unfortunately, despite great efforts in finding better therapies, high-grade glioma remains among the most devastating and deadliest of all human cancers. During recent years, genetic and molecular alterations that underlie this disease have been identified and advanced our basic knowledge about gliomagenesis. Moreover, understanding the molecular biology has also led to the development of genetically engineered mouse models that resemble many of the features of human gliomas. Ideally, such "patient-like" models should be instrumental for preclinical testing of novel therapeutics, but thus far they have not yet been widely implemented for this purpose. This review will discuss the advantages and shortcomings of the established high-grade glioma mouse models with emphasis on their potential applicability for preclinical testing of novel drugs and treatment regimens. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：714 / 723

页数：10

共 87 条

[1]

Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas [J].

Aboody, KS ;

Brown, A ;

Rainov, NG ;

Bower, KA ;

Liu, SX ;

Yang, W ;

Small, JE ;

Herrlinger, U ;

Ourednik, V ;

Black, PM ;

Breakefield, XO ;

Snyder, EY .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (23) :12846-12851

[2]

TRANSGENIC AND GENE DISRUPTION TECHNIQUES IN THE STUDY OF NEUROCARCINOGENESIS [J].

AGUZZI, A ;

BRANDNER, S ;

ISENMANN, S ;

STEINBACH, JP ;

SURE, U .

GLIA, 1995, 15 (03) :348-364

[3]

Analysis of tissue chimerism in nude mouse brain and abdominal xenograft models of human glioblastoma multiforme:: What does it tell us about the models and about glioblastoma biology and therapy? [J].

Antunes, L ;

Angioi-Duprez, K ;

Bracard, SR ;

Klein-Monhoven, NA ;

Le Faou, AE ;

Duprez, AM ;

Plénat, FM .

JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2000, 48 (06) :847-858

[4]

Epidermal growth factor receptor and Ink4a/Arf:: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis [J].

Bachoo, RM ;

Maher, EA ;

Ligon, KL ;

Sharpless, NE ;

Chan, SS ;

You, MJJ ;

Tang, Y ;

DeFrances, J ;

Stover, E ;

Weissleder, R ;

Rowitch, DH ;

Louis, DN ;

DePinho, RA .

CANCER CELL, 2002, 1 (03) :269-277

[5]

Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease [J].

Backman, SA ;

Stambolic, V ;

Suzuki, A ;

Haight, J ;

Elia, A ;

Pretorius, J ;

Tsao, MS ;

Shannon, P ;

Bolon, B ;

Ivy, GO ;

Mak, TW .

NATURE GENETICS, 2001, 29 (04) :396-403

[6]

BETA DA, 2007, THER CLIN RISK MANAG, V3, P707

[7]

GROWTH OF HUMAN GLIOMAS IN IMMUNE-DEFICIENT MICE - POSSIBLE MODEL FOR PRE-CLINICAL THERAPY STUDIES [J].

BRADLEY, NJ ;

BLOOM, HJG ;

DAVIES, AJS ;

SWIFT, SM .

BRITISH JOURNAL OF CANCER, 1978, 38 (02) :263-272

[8]

GROWTH AND CHEMOTHERAPEUTIC RESPONSE IN ATHYMIC MICE OF TUMORS ARISING FROM HUMAN GLIOMA-DERIVED CELL-LINES [J].

BULLARD, DE ;

SCHOLD, SC ;

BIGNER, SH ;

BIGNER, DD .

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1981, 40 (04) :410-427

[9]

ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice [J].

Charest, Al ;

Wilker, Erik W. ;

McLaughlin, Margaret E. ;

Lane, Keara ;

Gowda, Ram ;

Coven, Shanie ;

McMahon, Kevin ;

Kovach, Steven ;

Feng, Yun ;

Yaffe, Michael B. ;

Jacks, Tyler ;

Housman, David .

CANCER RESEARCH, 2006, 66 (15) :7473-7481

[10]

Comprehensive genomic characterization defines human glioblastoma genes and core pathways [J].

Chin, L. ;

Meyerson, M. ;

Aldape, K. ;

Bigner, D. ;

Mikkelsen, T. ;

VandenBerg, S. ;

Kahn, A. ;

Penny, R. ;

Ferguson, M. L. ;

Gerhard, D. S. ;

Getz, G. ;

Brennan, C. ;

Taylor, B. S. ;

Winckler, W. ;

Park, P. ;

Ladanyi, M. ;

Hoadley, K. A. ;

Verhaak, R. G. W. ;

Hayes, D. N. ;

Spellman, Paul T. ;

Absher, D. ;

Weir, B. A. ;

Ding, L. ;

Wheeler, D. ;

Lawrence, M. S. ;

Cibulskis, K. ;

Mardis, E. ;

Zhang, Jinghui ;

Wilson, R. K. ;

Donehower, L. ;

Wheeler, D. A. ;

Purdom, E. ;

Wallis, J. ;

Laird, P. W. ;

Herman, J. G. ;

Schuebel, K. E. ;

Weisenberger, D. J. ;

Baylin, S. B. ;

Schultz, N. ;

Yao, Jun ;

Wiedemeyer, R. ;

Weinstein, J. ;

Sander, C. ;

Gibbs, R. A. ;

Gray, J. ;

Kucherlapati, R. ;

Lander, E. S. ;

Myers, R. M. ;

Perou, C. M. ;

McLendon, Roger .

NATURE, 2008, 455 (7216) :1061-1068

← 1 2 3 4 5 6 7 8 9 →